Renal Cell Carcinoma

Renal Cell Carcinoma

  • Dennis France added an answer:
    Does anyone know of a mouse tumor cell line that has mutated Von Hippel Lindau (vHL) and/or that over-expresses HIF1-alpha?

    I am working with an agent which I think would be particularly effective In tumors that overexpress hif1-alpha (like human renal cell carcinoma), but I am not aware of mouse lines which display this. (It is an immunotherapy experiment, so orthotopic human line in nude SCID mmice will not be appropriate.)

    Dennis France

    Bill Kaelin at Harvard would know where to direct you as h has a long-standing interest in this area.

  • Anna Antonina Sobocińska added an answer:
    Is anyone familiar with 786-O renal cell carcinoma cell characteristics?
    Is there anyone familiar with renal cell carcinoma cell lines, such as 786-O? I am trying to find what kind of cells they are, for example if they are proximal tubule epithelial cells. Also, would the culture conditions RPMI 1640/ 10% fetal bovine serum media be ideal? Any idea or reference would be very appreciated.
    Anna Antonina Sobocińska


    In my lab We use RPMI 1640 with 10% FBS and antibiotics. It works well - 786-O is not demanding cell line and it grows really fast - as well as for an example ACHN cell line. Please be aware of which cell type would you like to work on - clear cell, papillary and so on - sometimes they are with wrong description. If you have any more questions please do not hesitate to ask me. Have a nice day.

  • Jordan Jahrling added an answer:
    Can anyone suggest a good housekeeping for western blot analysis of normal kidney and renal cell carcinoma tissue homogenates?

    We normally use beta Actin for normalizing RCC cell lysates. We tryed both beta actin and tubulin on tissue homogenates without any good results.

    Thank you

    Jordan Jahrling

    Can I assume you're using whole cell homogenates and did not fractionate (ie nuclear, cytosolic, membrane, etc)? If so you can also give GAPDH (35kDa) or Cofilin (20kDa) a try. If you have higher MW areas clean on your blots, you may try Vinculin (125kDa)

  • Divaker Choubey added an answer:
    How to encourage spontaneous immortalization of kidney cancer primary cells?

    Is there a way to encourage spontaneous immortalization or proliferation of renal cell carcinoma primary cells? These are cancer epithelial cells. I have no problems growing the cells (DMEM supplemented with 10% FBS), but they grow slowly and undergo senescence after 4-5 passages.

    Divaker Choubey

    One way to promote immortalization of the primary murine fibroblasts is to maintain cultures at an appropriate cell density. However, it is difficult to predict whether epithelial cell would respond similarly. Therefore, I would plate cells at higher cell density (as opposed to lower cell density) to assess the response of cells.

  • Gregor Babaryka added an answer:
    Does anyone know how to reliably differentiate between adrenal adenoma from metastatic RCC in adrenal gland?

    IHC, EM or simple histology - everything is OK, but I need 100% of assurance.

    Gregor Babaryka

    RCC should be positive for the immunohistochemical markers cd10 and rcc, weakly positive for ckpan. Adrenal Adenoma should be positive für inhibin, possibly for melanA  and weakly positive for synaptophysin. Both should be positive for vimentin...In deed, distinction can cause Problems, good question...

  • Shruthi Kanthaje added an answer:
    How can I dissolve Sorafenib tosylate?

    Hi all, If anybody is using sorafenib (a multikinase inhibitor used as a chemotherapeutic agent in liver cancer, renal cell carcinoma etc.,) for in vitro studies? Literature suggests its solubility in DMSO is 200mg/ml. But in our lab it does not dissolve even at 1mg/ml  (DMSO). It is not dissolving in water. If anybody has used it.. please let me know how you have worked with it?

    Shruthi Kanthaje

    Youtake oh... Thank you for the response...Which sorafenib do you use?

  • Yang Gao added an answer:
    Is it necessary to starve the cells prior to any drug treatment?
    I want to check effect of my drug U0126 on cellular proliferation (cell line A498). How can I decide the time of incubation with drug and after how much time I should proceed with proliferation assay?
    Yang Gao

    Interesting point Lidia.Could you elaborate?

  • Go J Yoshida added an answer:
    TGF-β–induced EMT in renal cell carcinoma lines?


    does anybody has got personal experience with TGF-β–induced EMT in renal cell carcinoma lines?

    Thanks a lot


    Go J Yoshida

    I think the following reference would be informative for you. The synergistic effect of TNF-alpha and TGF-beta ligand is considered to be important for tumor cells as well as pigmental epithelial cells in the retina to exhibit EMT. 

    • [Show abstract] [Hide abstract]
      ABSTRACT: Aberrant epithelial-mesenchymal transition (EMT) is involved in development of fibrotic disorders and cancer invasion. Alterations of cell-extracellular matrix interaction also contribute to those pathological conditions. However, the functional interplay between EMT and cell-extracellular matrix interactions remains poorly understood. We now show that the inflammatory mediator tumor necrosis factor-α (TNF-α) induces the formation of fibrotic foci by cultured retinal pigment epithelial cells through activation of transforming growth factor-β (TGF-β) signaling in a manner dependent on hyaluronan-CD44-moesin interaction. TNF-α promoted CD44 expression and moesin phosphorylation by protein kinase C, leading to the pericellular interaction of hyaluronan and CD44. Formation of the hyaluronan-CD44-moesin complex resulted in both cell-cell dissociation and increased cellular motility through actin remodeling. Furthermore, this complex was found to be associated with TGF-β receptor II and clathrin at actin microdomains, leading to activation of TGF-β signaling. We established an in vivo model of TNF-α-induced fibrosis in the mouse eye, and such ocular fibrosis was attenuated in CD44-null mice. The production of hyaluronan and its interaction with CD44, thus, play an essential role in TNF-α-induced EMT and are potential therapeutic targets in fibrotic disorders.
      Journal of Biological Chemistry 12/2009; 285(6):4060-73. DOI:10.1074/jbc.M109.056523

    + 2 more attachments

  • Joe Graymer added an answer:
    What is the treatment options for metastatic non clear cell RCC with brain mets?

    Brain mets and non clear cell histology were always the exclusion criteria for most of the recent clinical trials that approved targted therapy for RCC, and treatment of those patients is currently debatable. please find and share the way you mange this group of patients 

    Joe Graymer

    Is this of any application in this case?

    Anticancer Drugs. 2008 Apr;19(4):431-3. doi: 10.1097/CAD.0b013e3282f5d336.

    Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent

    Fujiwara Y(1), Kiura K, Tabata M, Takigawa N, Hotta K, Umemura S, Omori M, Gemba
    K, Ueoka H, Tanimoto M.

    Author information:
    (1)Department of Hematology, Oncology and Respiratory Medicine, Okayama
    University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,
    Okayama, Japan.

    A 60-year-old Japanese man presented to our hospital with a painful left hip.
    Computed tomography showed a tumor in the left kidney and metastases in the left
    gluteus maximus muscle and lung. The pathological diagnosis of a biopsy specimen
    obtained from a metastatic lesion in the left gluteus maximus muscle was
    sarcomatoid renal cell carcinoma. On admission, his general condition was
    extremely poor. He was confined to bed because of severe left hip pain and
    confusion, possibly caused by hypercalcemia. This seriously ill patient suffering
    from advanced sarcomatoid renal cell carcinoma was treated with single-agent
    gemcitabine, resulting in symptom relief and a dramatic improvement in his
    status; all of the tumors had regressed significantly by the 11th dose of
    gemcitabine. These findings indicate that single-agent gemcitabine is one of the
    few chemotherapeutic agents effective for palliation in patients with sarcomatoid
    renal cell carcinoma, even those with poor performance status.

    PMID: 18454054 [PubMed - indexed for MEDLINE]

    Cancer Chemother Pharmacol. 2008 Feb;61(2):223-9. Epub 2007 Apr 19.

    Pharmacokinetics of gemcitabine in tumor and non-tumor extracellular fluid of
    brain: an in vivo assessment in rats employing intracerebral microdialysis.

    Apparaju SK(1), Gudelsky GA, Desai PB.

    Author information:
    (1)College of Pharmacy, University of Cincinnati Medical Center, Cincinnati, OH
    45267-0004, USA.

    PURPOSE: Gemcitabine is a pyrimidine nucleoside analogue anticancer agent that
    has shown promising anti-tumor activity in several experimental models of brain
    tumor. However, the pharmacokinetic behavior of gemcitabine in the central
    nervous system, especially in brain tumors is currently not well understood. In
    this study we evaluated the gemcitabine brain extracellular fluid (ECF) in normal
    rats and in ECF obtained from tumor- and tumor-free regions of glioma-bearing
    rats, to better understand the availability of the drug to brain and brain
    METHODS: The brain ECF pharmacokinetics of gemcitabine were investigated
    employing intracerebral microdialysis following intravenous administration of 10,
    25 and 100 mg/kg doses in male Sprague-Dawley rats. In the second phase of the
    study, gemcitabine (25 mg/kg) was intravenously administered in rats implanted
    with C6 gliomas and ECF samples were simultaneously obtained from the tumor and
    tumor-free regions of the brain. Serial blood samples were obtained for
    evaluating the plasma pharmacokinetics of gemcitabine. Non-compartmental approach
    was employed for the analyses of the brain ECF and plasma pharmacokinetics of
    RESULTS: Following intravenous administration, gemcitabine rapidly distributed
    into rat brain. At doses equivalent to 10, 25 and 100 mg/kg, the brain ECF
    gemcitabine AUC (area under the plasma concentration--time curve measured over
    the last sampling time point) values were 2.46 +/- 0.7, 3.20 +/- 1.1, and 9.06
    +/- 3.0 microg h/ml, respectively. The brain ECF concentrations of gemcitabine
    declined in parallel with plasma concentrations. At the three doses evaluated,
    the relative brain distribution coefficient (AUC brainECF/AUC plasma) of
    gemcitabine ranged from 0.07 to 0.09 suggesting limited gemcitabine availability
    to brain tissues. Studies on C6 glioma-bearing rats revealed that following an
    intravenous dose of 25 mg/kg, the AUC values in the tumor-free and tumor-brain
    regions were 4.52 +/- 2.4, and 9.82 +/- 3.3 microg h/ml, respectively. Thus, the
    AUC of gemcitabine in the tumor ECF was on average 2.2-fold greater than the
    corresponding value in the tumor-free ECF of the brain. Plasma pharmacokinetics
    of gemcitabine remained unaltered in tumor-bearing animals, when compared to
    plasma pharmacokinetics in healthy animals.
    CONCLUSIONS: Our findings suggest that the overall brain exposure to gemcitabine
    is likely to be low as evident from the relative brain distribution coefficient
    of <0.1. However, the exposure is likely to be considerably higher in the brain
    tumor relative to tumor-free regions of the brain. The higher drug levels in
    brain tumor compared to the non-tumor region may facilitate selectively higher
    cytotoxicity against brain tumor cells.

    PMID: 17443325 [PubMed - indexed for MEDLINE]

    Regarding the general problems in brain metastasis, I always was in doubt about the so called: 'eloquent' metastasis, that do produce an specific neurological deficit, and thus, the suspicion exists that any local therapy would make the same lesion the metastasis induced, and end result will be the same, however, some 'eloquency' is needed for diagnosing a brain mts, you perform standard CNS imaging as part of work-up only for certain tumors, but: are there any series, if somebody attempted this, of 'eloquent' brain mts invasively treated?


  • Mauricio Marti Brenes added an answer:
    What methods are used to detect similarities between AML (angiomyolipoma) and RCC (Renal Cell Carcinoma) ?

    Thank you for this information.

    Mauricio Marti Brenes

    Las diferencias a nivel molecular y a nivel imagenologico, las que expone el articulo anterior y aun mas simple, se difencian muy bien en una tomografia axial computarizadas

  • Amit Gupta added an answer:
    How can I make a single cell suspension from renal cell carcinoma? Does a different tissue have a different protocol?

    If you have the answers, I hope you also tell me the titles of articles your answers are from.

    Amit Gupta

    Try this one it might help you.

    Here I am posting few suggestions given by one of RG member that will help you in protocol optimization.

    I thing forming single cell suspension will vary....but I am sure you need to check it

    Best wishes

  • Maurizio Salvadori added an answer:
    How common is native kidney renal cell carcinoma in a renal transplant patient with stable graft function for 26 years?

    Have one such patient who underwent nephrectomy with stage 2 RCC. What should be the changes in immunosuppression in such scenario?

    Maurizio Salvadori

    The frequency is higher than estimated. We should to check by US al least every two years

  • John Samuel Banerji added an answer:
    What is the best time for renal angioembolization (RAE): before nephrectomy in large hypervascular or locally advanced renal cell carcinoma?

    The ideal timing of nephrectomy after embolization is unclear.

    John Samuel Banerji

    Dear Alireza,

    I don't think I would agree with Dr.Theodor Klots, with regards to the timing of RAE.

    One week is too early-ideally it is done just a day before surgery-sometimes even hours before.You want to operate before tumor lysis syndrome kicks in. Also, the longer one waits, the more edema and destruction of surgical planes is there, especially at the hilum.

    In fact, there are a few papers, where a balloon catheter is threaded unto the renal artery, in the OR suite, and then left in. After opening, the balloon is inflated, to occlude the arterial inflow, in larger tumors, before ligating the renal artery.

    One of the major problems during nephrectomies for very large vascular tumors, is the "venous hypertension"-especially in the presence of tumor thrombus or large collaterals.

    Using RAE just prior to surgery, in that setting is useful.

  • Gamal Abdul Hamid added an answer:
    What is the best treatment option for patients with ccRCC and CML?
    Would you combine imatinib with TKIs or mTORI?
    Gamal Abdul Hamid

    Dear Anna

    I think there is no clear guidelines for the treatment of concurrent RCC and CML.  The determination of the CML status as primary or secondary is important.

    I think after nephrectomy the determination of suspected getetic mutation is important before begining Sunitinib, sorafenib or Beva.

    The combination of two target therapies is effective , but what is mandatory to register the genetic mutation during treatment.

  • Shomik Sengupta added an answer:
    Can anyone help with an undifferentiated carcinoma of kidney?
    A 46 years old male patient with locally T3 renal cancer with huge interaortocaval lymphadenopathy and 5 cm parenchymal lung metastases and biopsy proven undifferentiated carcinoma has uncontrollable abdominal pain resistant to narcotics. Is a salvage surgery a feasible option before systemic treatment?
    Shomik Sengupta

    Cytoreduction or palliation are justifiable indications for nephrectomy in the presence of metastases. I presume this is undifferentiated adenocarcinoma of the kidney? These tend to have poorer response to systemic therapy - if the majority of the disease burden is in the kidney & lymph nodes, and they appear surgically resectable, I would definitely recommend surgery. It may be worth also exploring whether the lung lesion can also be resected perhaps thoracoscopically. 

    • [Show abstract] [Hide abstract]
      ABSTRACT: Renal cell carcinoma (RCC) often presents in its metastatic form, or progresses after curative treatment. While the management of metastatic RCC has historically been mainly surgical, contemporary approaches often incorporate systemic immunotherapy. This review examines the current indications and scope of surgical treatment of patients with metastatic RCC. Surgery is sometimes indicated for symptom palliation at either the primary or secondary sites. However, other less invasive therapies may be equally effective, and should be considered carefully. Cytoreductive surgery prior to immunotherapy appears to confer a survival advantage, but only selected patients are suitable for this treatment regimen. Primary immunotherapy followed by surgical removal of the tumour in partial responders is an alternative treatment strategy, which has not yet been evaluated as in randomized trials. As immunotherapy develops further, the precise timing and role of surgery in multimodality treatment will need to be carefully evaluated. Occasionally, the complete surgical excision of metastases, and the primary tumour, if present, is feasible and this may prolong survival. Empirically, it would seem that such patients should also be treated with adjuvant immunotherapy, as eventual relapse is frequent. Surgery with the aim of inducing spontaneous tumour regression is not justifiable, given the rarity of this phenomenon.
      World Journal of Urology 08/2005; 23(3):155-60. DOI:10.1007/s00345-005-0504-6
  • Mary Khorami asked a question:
    What is the colony morphology of renal cell carcinoma? How to diagnose them?
    Please share a picture of renal cell carcinoma colony before staining.
  • Kathryn Parker added an answer:
    How to avoid rapid pH fluctuation in DMEM medium?
    Before storing the DMEM (sigma high glucose) at 4°C. I set the pH 7.2, and next day I checked the pH of the medium. After warming up at 37°C the pH rose to 7.8. What could be the reason and will it effect the growth of my cell line? I am using ACHN and A498 (renal cell carcinoma cell line).
    Kathryn Parker
    Dear Gerald and Wolfgang,

    Thank you Gerald for your great answer! It has certainly cleared up a few things: I will be sure to keep the caps on my media bottles tight, this was something I probably wasn't doing enough at some points.

    So thanks to both of you, your answers have been very helpful. I am new to this forum but so far all my experiences with it have been very good, I think it is a big success!

    Kind regards and many thanks again,
  • Samer Salah added an answer:
    What is the current practice in the absence of good evidence of cytoreductive nephrectomy in the current era of targeted therapy for metastatic RCC?
    Are you for or against performing cytoreductive nephrectomy for patients with metastatic clear cell- renal cell carcinoma who are treated with VEGF-TKI therapy !
    In the absence of evidence, one would like to listen to the opinions and have an idea on the current practice. Any supporting evidences are highly appreciated.
    Samer Salah
    Dear Stephan Kiessig,
    Thank you so much for the attached article. Interesting data ! However, my question is about patients with METASTATIC renal cell carcinoma who are treated with the novel targeted therapies, and the evidence that you provided suggests a benefit of immune therapy as an adjuvant therapeutic strategy following nephrectomy in patients with NON-METASTATIC renal cell carcinoma.
    There is debate regarding the necessity of performing a cytoreductive nephrectomy in patients with metastatic renal cell carcinoma who are treated with VEGF-TKI therapy. The evidence supporting survival advantage for cytoreductive nephrectomy in the metastatic setting is evident only for patients treated with Interferone Alfa (based on two randomized trials).
    In the absence of evidence supporting the benefit in patients treated with targeted therapy, it is wise to see the opinions and the current practice of experts in the field, and to see what is their opinion in that clinical setting and whether there are subgroups of patients (depending on the extent of metastasis, the bulk of the primary, the MSKCC risk category, or any other factors) that are likely to derive benefit. And this is the main reason why I added this question for discussion.
    Please check the attached reference which discusses this controversial issue.
  • Samer Salah added an answer:
    What is the standard therapy for sarcomatoid renal cell carcinoma with brain metastasis?
    I have a 52 year old male patient who presented with transient dysarthria and numbness at the right side of the face. The patient was transferred to the emergency room where an MRI of his head showed two lesions; one in the left parietal lobe, and the other is located in the right cerebellar hemisphere. The size of the lesions is around 1.5 cm in maximum diameter each. Both lesions were highly suggestive of metastasis. The neurological symptoms resolved completely within few hours of his presentation. A CT scan of chest and abdomen showed renal mass arising from the upper pole of the right kidney and invading the peri-nephric fat, with possible invasion of psoas muscle, and an enlarged subcarinal LN (around 3 cm in maximum dimension). CT guided biopsy from the kidney mass was performed at our center and confirmed the diagnosis of sarcomatoid renal cell carcinoma (not sarcoma arising in the kidney. It is the sarcomatoid subtype of RCC).
    Bronchoscopy and EBUS biopsy from the subcarinal LN was carried out and showed negative LN. Additionally, an MRI for the abdominal wall was not suggestive of psoas muscle invasion by the tumor as it showed clear separation of the psoas muscle and the tumor, and as such, the kidney mass is resectable according to the opinion of the urologist at our center. The patient has history of coronary artery disease, had previous catheterization and coronary stent two years ago, he is also a known case of hypertension. His hypertension and coronary artery disease are well controlled with medications, his left ventricular ejection fraction is ok, and he is now asymptomatic and has a peformance status of 0.
    What is the best therapeutic option for this patient ?
    Samer Salah
    Dear Tamer,
    Thank you for your suggestion about gemcitabine if chemotherapy is needed in the future. Any supportive evidence for that ?
  • Ladislaus L. Torday asked a question:
    What is your opinion? Should we stop TKI treatment after a metastatic renal cell cancer patient reached complete remission?
    Think about side effects and the risk of recurrence.. :)

Topic followers (1,563) See all